Lilly’s Donanemab Slows Cognitive Decline; FDA Filing Imminent

Full Approval Sought After Accelerated Nod Denied Previously

 
• By Mandy Jackson
  
Alzheimer's disease on MRI
Donanemab slowed cognitive decline in Phase III • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D